Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

DOI Full Paper Access

143

Citations

19

References

2015

Year

Tsutomu Takeuchi, Yoshiya Tanaka, Manabu Iwasaki, Hiroaki Ishikura, Satoshi Saeki, Yuichiro Kaneko

Annals of the Rheumatic Diseases

Abstract

NCT01649999; Results.

References

	Year	Citations

Page 1